S erosive rheumatoid arthritis (RA), producing producing 'remission induction' with possibly fewer side-effects, but a slightly higher risk of later relapse. progressive and serious functional impairment, remains a difficult therapeutic challenge. Cytotoxic disease-CP has also been used to treat vasculitis complicating RA [3, 4] . There are a few reports of its use in some modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX ), azathioprine (AZA) and of the more severe systemic complications of RA including pyoderma gangrenosum [5], Felty's syncyclophosphamide (CP), were first used to treat RA in the 1950s [1] . Their use was initially restricted to drome [6 ] and the corneal melt syndrome [7] . We have reviewed the literature relating to AZA and patients with refractory or life-threatening systemic disease due to concerns about toxicity. In the past CP with respect to treatment in RA. We outline here the pharmacology and toxicity of these drugs, and give decade, a new approach to treating RA has evolved. Rheumatologists now advocate earlier intervention some advice for monitoring. with DMARDs, largely due to the fact that the tradi-AZATHIOPRINE tional pyramidal approach to treatment has not been Pharmacology shown to improve clinical, functional or radiographic AZA is a cycle-specific antimetabolite which was outcome significantly. MTX is probably the most first synthesized in 1957 and first reported to be of widely prescribed DMARD in RA and its use is also potential use in RA in 1964 [8] . In 1981, it was increasing in other rheumatic diseases. This has been approved by the US Food and Drug Administration the subject of a recent review in this journal [2] . AZA for use in RA. As a purine analogue, AZA derives is still frequently used, but perhaps more often now as most of its biological effects from the active a steroid-sparing agent, whereas CP is rarely used to ribonucleotide metabolites of its initial metabolite treat uncomplicated RA.
6-mercaptopurine (6-MP). AZA interferes with the de CP and AZA are also used to treat other rheumatic novo synthesis of inosinic acid via feedback inhibition diseases and in particular CP is now currently used by of 6-thioinosinic acid. It also inhibits the interconverrheumatologists for systemic connective tissue diseases sion of purine bases such as inosine to adenine and including systemic lupus erythematosus (SLE ) and the guanine ribonucleotides. A small amount of 6-MP is systemic vasculitides, such as polyarteritis nodosa, also incorporated into RNA and DNA in the form of Wegener's granulomatosis, microscopic polyangiitis 6-thioguanine. Most ingested AZA is excreted in the and Churg-Strauss syndrome. Most published studies urine in the form of thiouric acid, 10% of the drug is on its role in arthritis treatment are from the 1960s excreted unchanged. Following absorption, AZA is and 1970s, but concerns about toxicity and the increasrapidly distributed throughout the body and plasma ing use of other immunosuppressive agents such as levels remain low (1 mg/ml ). Determination of plasma MTX have led to a gradual reduction in the use of levels is not useful in clinical practice. AZA has a oral CP for RA with time. It tends now only to be plasma half-life of 3 h, is moderately protein bound used in extreme cases.
(30%), and both unchanged drug and metabolic prodVarious protocols concerning the dose and method ucts can be dialysed. Diminished action of any of the of administration of CP have been advocated without specific enzymes required for AZA metabolism, either consensus. These range from continuous oral CP by competition from co-administered drugs (e.g. alloadvocated by the NIH group in Wegener's granulopurinol-blocking xanthine oxidase) or through genetic matosis to pulsed oral and i.v. regimes either weekly, enzyme deficiencies (e.g. Lesch Nyhan syndromefortnightly or monthly (with or without i.v. steroids) absent hypoxanthine guanine phosphoribosyltransferand monthly i.v. CP without steroids to treat SLE. It ase, or thiopurine methyltransferase deficiency due seems likely from the available evidence that pulsed to genetic polymorphism) may greatly increase AZA i.v. CP is as effective as continuous oral CP for toxicity and reduce efficacy [9] [10] [11] .
Efficacy
When considering the efficacy of a DMARD, three $ Is joint inflammation suppressed-leading to a active joint count, grip strength and total number of reduction in pain and stiffness and an improvement synovial effusions. Erythrocyte sedimentation rate in functional ability?
( ESR) and latex titre did not change. Benefit was $ Is radiological damage slowed or prevented? evident after 6 weeks of treatment; however, the drug $ What is the toxicity profile?
produced further benefit between 6 and 16 weeks. Analysis of the same parameters measured after a Unfortunately, it is extremely difficult to answer mean period of 40 months follow-up indicated that many of these questions reliably when considering the AZA continued to exert a disease-suppressive effect efficacy of AZA due to fundamental flaws in study [19] . Eleven out of 12 patients either maintained their design. These include qualitative methodological defiinitial beneficial response or showed further improveciencies, inadequate sample size, short duration of ment. Four patients discontinued therapy because of follow-up, variation in drug dosage from one study to lack of efficacy and one because of nausea. Goebel another, and the fact that the majority of studies were et al.
[15] compared AZA 1.5-2.9 mg/kg/day vs plaundertaken in patients with established, advanced or cebo in a controlled clinical cross-over study for two refractory disease. These facts must all be taken into 12 week periods. There was a 60% improvement in the consideration when critically reviewing the literature.
joint count index in AZA-treated patients as compared Placebo-controlled studies. Several placebo-controlwith a 30% deterioration in placebo-treated patients. led studies have demonstrated that AZA is efficacious This was associated with a decrease in immunoglobulin in RA [12] [13] [14] [15] [16] [17] [18] . These studies are summarized in levels; however, rheumatoid factor (RF ) levels did not Table I. change. De Silva and Hazleman [16 ] switched half of Mason et al. [12] demonstrated the corticosteroida group of 32 AZA-treated patients to placebo after a sparing activity of AZA in a group comparative study mean period of 6 yr. Withdrawal of AZA had a against placebo. From an initial mean prednisolone detrimental effect on disease activity. Similar findings requirement of 11.8 mg, there was a reduction in were reported by Cade et al. [20] who followed 16 dosage of 36%, achieved without clinical deterioration, AZA-treated patients for up to 6 yr, noting subjective over the course of 9 months. Levy et al. [13] conducted improvement in all, with a striking improvement in a 12 month double-blind cross-over study of AZA ability to work. ESRs tended to fall, but not necessarily 3 mg/kg/day vs placebo in 18 rheumatoid patients.
in parallel with systemic improvement. Positive tests Eighty-three per cent of AZA-treated patients for RF became negative in some patients, and others improved (active joint count, grip strength, duration showed a fall in titre. When treatment was changed to of early morning stiffness). Urowitz et al. [14] underplacebo in these patients, a relapse occurred within 8 took a double-blind cross-over study comparing AZA weeks. There was prompt improvement when AZA against placebo in 17 patients who had been unresponwas resumed; however, several patients did not reach sive to conventional anti-rheumatic therapy, giving their previous state of well-being until after 6 or each treatment for 16 weeks. AZA resulted in a statistically significant improvement in articular index, total 7 months of treatment. Woodland et al. [17] 49 patients/35 completed 36%; 1 AZA patient withdrawn due to adverse event, 9 placebo Levy, 1972 [13] randomized double-blind cross-over 12 months Significant improvement in AZA group; 2 drop-18 patients/16 completed outs due to thrombocytopenia and GI intolerance randomized double-blind cross-over 4 months AZA > placebo; no drop-outs due to adverse [14] 17 patients events Goebel, 1976 randomized double-blind crossover 24 weeks AZA > placebo; 4 drop-outs due to adverse [15] 34 patients/30 completed events (AZA) De Silva, 1981 randomized double-blind placebo 8 months Substitution of placebo for active drug resulted [16 ] substituted for active drug in clinical deterioration; 1 drop-out due to drug withdrawal AZA 32 patients Woodland, 1981 randomized double-blind half-dose 6 months Full dose more effective; drop-outs due to [17] AZA (1.25 mg/kg/day) vs fulladverse events (7 full-dose AZA, 4 half-dose dose AZA (2.5 mg/kg/day) vs AZA, 2 placebo) placebo 42 patients/29 completed Kvien, 1986 [18] randomized [25] demonstrated that MTX-treated patients showed order to achieve the maximum effect. Kvien et al. [18] conducted a comparative, double-blind, parallel 16 significantly less radiographic progression (new erosions, total joint score) than AZA in a study of 64 week clinical trial of AZA vs placebo in 32 patients with juvenile RA receiving prednisolone as a baseline patients with active RA who either had not responded, or who experienced significant side-effects while therapy. The majority of disease activity measurements changed in favour of the AZA group; however, statisreceiving parenteral gold and/or -penicillamine.
Radiographs of hands and feet were evaluated at the tically significant differences were found for only two disease activity measurements: patients' subjective start, and after 24 and 48 weeks by a blinded observer. [17] concluded that the a dose of 2.5 mg/kg/day should be administered in Hamdy et al.
[24] studied 42 patients with active synovitis who were unresponsive to one or more nonorder to achieve the maximum benefit, although adverse events were more frequent at higher dosage.
steroidal anti-inflammatory drugs (NSAIDs), gold and/or D-PEN. Patients were randomized to receive This study has been reviewed in the previous section. Cseuz et al. [22] undertook a small, comparative, 12 either AZA 100 mg/day or MTX 10 mg/week, orally, adjusted at pre-defined intervals, and evaluated proweek parallel, double-blind controlled study comparing daily AZA with 300 mg given only on Mondays (M ), spectively in a double-blind comparison for 24 weeks followed by an 18 month open phase. Both treatment Wednesdays ( W ) and Fridays ( F ) in 30 patients with RA in order to determine whether the pulsed regimen groups showed a significant improvement at week 24, compared with baseline status, in nine of the 10 efficacy would be as effective and less toxic than the daily regimen. There were two immediate drop-outs in the variables. Although there were no statistical differences between the two treatment groups at week 24, there 300 mg M, W and F group due to gastrointestinal side-effects. There were no significant differences in was a trend towards a more marked and rapid improvement in the MTX-treated group. By week 52 (open clinical assessments or toxicity between the two groups, suggesting that intermittent oral AZA therapy may phase), outcome measures were not statistically different from those at week 24. Two patients withdrew be an acceptable alternative to continuous daily treatment.
from each group by week 24 due to probable drugassociated side-effects; by week 52, eight additional These studies suggest that 2.0-2.5 mg/kg/day of AZA is necessary to maximize clinical effectiveness, patients had discontinued treatment. Arnold et al. [27] randomized 53 patients previously treated with either although adverse events may be more common at this dosage.
gold or D-PEN to receive either AZA 100 mg/day or MTX 10 mg/week modified according to efficacy and Does AZA influence radiographic progression? Prevention of new erosions suggests good control of laboratory parameters of toxicity. Concurrent NSAIDs and oral or intra-articular steroid were prescribed and disease itself rather than just relief of symptoms. Four studies have evaluated the influence of AZA on altered according to the judgement of the supervising clinician. By week 24, there were no significant differradiographic changes and provide conflicting results [23] [24] [25] [26] . Currey et al. [23] demonstrated that both ences in clinical outcomes between the two groups, although inter-group differences were apparent with AZA and CP retarded radiographic deterioration in a randomized double-blind controlled trial of AZA vs respect to increased haemoglobin (Hb) and declining ESR in MTX-treated patients. Fifty per cent of patients either CP or gold over 18 months. The rate of radiological deterioration was similar in both AZA-and in both groups discontinued therapy by week 24 due to either lack of efficacy (nine MTX, six AZA) or Sambrook et al.
[28] undertook a retrospective study of AZA and 6-MP in comparison with MTX using adverse events (five MTX, seven AZA). After 1 yr, more than half of the patients in both groups disconlife-table analysis. Fifty-five patients took purine analogues, 100 mg/day (median), whilst 84 took MTX in tinued therapy because of lack of efficacy or adverse events. Adverse events were more common in MTXa median dose of 7.5 mg/week. By 12 months, 29.3% of patients had ceased purine analogues due to toxicity, treated patients; however, withdrawal rates were similar in both groups. The authors concluded that the compared with 19.3% for MTX. Toxicity severe enough to warrant cessation of therapy was rare after 8 months probability of a patient continuing either therapy for >18 months was low.
for either drug. At 12 months, only 26.5% of the purine analogue patients had achieved defined criteria for greater for AZA therapy than for MTX, while the combination remained the most active. Adverse effects improvement compared with 61.5% of the MTX patients (P < 0.05). The number of patients improving on the gastrointestinal tract and elevations of liver enzyme levels were the most frequent causes for dison purine analogues did not increase substantially after 5 months, whereas the number improving with MTX continuation. The authors concluded that combination therapy and MTX alone were superior to therapy with continued to 12 months. From these data, the authors concluded that low-dose MTX was superior to low-AZA alone for active RA, but were not statistically different in their effect on outcome assessment. In dose purine analogues in RA. Bell et al. [29] randomized 34 patients with active RA refractory to gold, 1995, Willkens et al.
[26 ] reported 48 week data on 110 of these patients who remained on the initially D-PEN and chloroquine in a 20 week double-blind randomized control trial of AZA (100-150 mg/day) vs randomly assigned regimen. The highest rate of dropout was in the AZA group; the highest percentage of MTX (10-15 mg/week). Eleven (eight AZA, three MTX ) patients withdrew from the study. Six of the patients remaining on the initially assigned regimen was in the MTX group. Virtually every parameter AZA withdrawals were due to side-effects. Efficacy of treatment, as defined by a 30% change from baseline studied showed at least a trend for MTX to be more effective. The combination of AZA plus MTX was in ESR, grip strength and number of active joints, was seen in five patients only (all MTX ) at study complethought to be neither more toxic nor more effective than MTX alone. A trend toward decreased radiotion, suggesting that MTX has a greater efficacy and is associated with fewer adverse events than AZA.
logical progression was seen in the MTX-treated patients. This study established that the combination Jeurissen et al. [30] randomized 64 patients in whom gold and/or D-PEN treatment was unsuccessful to a of MTX and AZA was not associated with more toxicity than treatment with single agents; however, 48 week double-blind, randomized trial comparing AZA (100 mg daily) and MTX (7.5 mg weekly), modienhanced efficacy was not seen. Forre et al. [32] randomized 24 patients with estabfied after 8 weeks according to efficacy. At week 24, improvements in 12/13 clinical variables were seen in lished RA to receive either CS (10 mg/kg/day) or AZA (2.5-3 mg/kg/day) for 26 weeks in an open, controlled, MTX-treated patients vs 6/13 in AZA-treated patients. Improvements in swollen joint count, visual analogue randomized study. Although no statistically significant difference in benefit was observed between the two score ( VAS ) pain score, ESR, C-reactive protein, Hb and disease activity score were significantly greater at groups, statistically significant improvements in 5/13 clinical parameters were observed within CS-treated 24 weeks in MTX-treated patients by area under the curve analysis. A significant overall improvement (dispatients compared to 1/13 within the AZA group, and a greater and more rapid reduction in dosage of ease activity score) was found in 7/20 AZA-treated patients and 18/30 MTX-treated patients at 24 weeks, concomitant prednisolone treatment was possible in CS-treated patients. Kruger et al. [33] undertook a 6 and in 6/12 AZA-treated patients and 19/25 MTXtreated patients by 48 weeks. The number of withmonth, prospective, randomized double-blind multicentre study comparing AZA (1.5-2.0 mg/kg) and CS drawals due to side-effects was significantly higher in the AZA-treated group. After 48 weeks, only 12 of the (10 mg/kg) in 117 patients with RA, and demonstrated that efficacy and tolerability were comparable in both AZA-treated patients (36%) compared to 25 (81%) of the MTX-treated group remained on treatment.
groups. Ninety-two patients completed the study, treatment was discontinued prematurely in 12 patients in Analysis of the radiological changes in these patients also showed more improvement in the MTX-treated each group. Berry et al.
[34] undertook a single-blind trial of AZA and D-PEN. Assessments at 3 and 12 group. The authors concluded that MTX was superior to AZA for treating RA with a more rapid and months showed no significant differences in pain, articular index, joint swelling, grip strength or morning sustained clinical improvement sustained after 1 yr, accompanied by a lower rate of serious adverse reacstiffness between the two groups. There was, however, a trend in favour of D-PEN in most of these measuretions. Willkens et al.
[31] compared the relative safety and efficacy of AZA, MTX and the combination of ments and in laboratory markers of disease activity. Rises in Hb levels and falls in latex titre and ESR were both in the treatment of active RA. Two hundred and nine patients with active RA unresponsive to injectable greater in the D-PEN group, although many of these differences failed to reach statistical significance. Paulus gold, auranofin or D-PEN were entered into a 24 week, prospective, controlled, multicentre trial and et al.
[35] entered 206 patients treated unsuccessfully with gold into a prospective, controlled, double-blind, randomly assigned to one of three treatment groups. One hundred and fifty-eight patients (75%) finished 24 multicentre trial comparing AZA with D-PEN. One hundred and thirty-four patients completed 24 weeks weeks of the study. Response rates were >30% for all outcome measures. Combination therapy was not statof therapy. Both drugs had similar efficacy; however, AZA was slightly better tolerated. Currey et al. [23] istically superior to MTX therapy alone; however, both combination therapy and MTX alone were superior to compared AZA, CP and gold under double-blind conditions for 18 months in patients with relatively AZA alone when patients were analysed by intent-totreat analysis and with withdrawals treated as therapy early RA (50% had disease for <2 yr). All three agents produced comparable clinical improvement; however, failures. If only patients who continued taking the therapy were analysed, the mean improvement was AZA and CP both facilitated a reduction in cortico-steroid dosage and retarded radiological deterioration. and the overall physician rating of response was good or excellent in 11 patients. Two patients had to disconThere were fewer patient withdrawals in AZA-treated patients. [43, 44] , MTX/HC [45, 46 ] and prednisolone [47, 48] .
remission, seven partial remission, one no response. Four patients developed a malignancy during therapy, Waterworth [42] conducted an open study to assess the combination of AZA and SZP in 13 patients with three of whom died (five patients in this group had previous malignancies). Adverse events including RA who had not been well controlled by either agent alone. On combination therapy of SZP (10 patients severe infections, thrombocytopenia, stomatitis, diarrhoea and leg ulcers were common, occurring in all 1 g, three patients 2 g) plus AZA (one patient 50 mg, 12 patients 100 mg) for a mean duration of 14 months, but six of the patients studied. The authors concluded that although this combination may have merit, it the number of swollen joints had decreased in nine, should only be used in intractable RA when convenorder to determine the nature, frequency and potential predictors of side-effects. Eleven AZA-treated patients tional management has not provided satisfactory control. They also recommended that CP should be (30%) vs 31 (33%) MTX-treated patients experienced a major side-effect; gastrointestinal symptoms and replaced with a non-alkylating agent due to concerns regarding the absolute risk of malignancy. In 1995, cytopenias were common in the AZA group. In addition, the majority of patients in each group (29 AZA, McCarty et al. [45] studied the effect of combination therapies in an open sequential study of 169 patients, 79 MTX ) experienced one or more minor side-effect during the follow-up period. The haematological 69 of whom received a regimen combining pulse oral MTX, AZA and HC (MAH ) in conjunction with adverse events of AZA at low dosage of 1-3 mg/kg/day are limited and include macrocytosis, leucopenia, and NSAIDs, intra-articular and oral corticosteroids. The entire patient cohort showed improvement in every less commonly megaloblastic anaemia or pure red cell aplasia [50] [51] [52] . Low activity of thiopurine methylvariable except Hb at the time of the last visit (P < 0.0004). Disease remission was achieved in 45% transferase ( TPMT ) has occasionally been reported as a cause of AZA-related bone marrow toxicity in of the MAH patients, near remission in 69%. On multivariate analysis, MAH patients were improved patients with a variety of conditions, including one with RA [53] ; however, other mechanisms also contribonly in American Rheumatism Association functional class compared with the other groups (P < 0.001).
ute since similar events have also been reported in patients with normal TPMT levels [54] . Severe bone Overall mortality rates did not differ significantly from that of the general population. Langevitz et al. [46 ] marrow suppression is rare unless associated with the simultaneous use of allopurinol [55, 56 ] ; this usually also reported the MAH combination in 12 patients with intractable RA. Seven patients responded to this reverses after cessation of therapy. Urowitz et al. [14] noted leucopenia in five out of 17 patients treated with combination, three patients achieving near or complete remission (swelling and tenderness of one joint or less).
AZA which required slight reduction in dosage but not cessation of therapy. In a later study of two dosage Hantzchel et al. [47] and Bijlsma et al. [48] both studied the effect of glucocorticoid therapy in conjunclevels, Urowitz et al. [21] showed that neutropenia is not dose related, responds rapidly to treatment withtion with AZA in small numbers of patients with RA, arriving at different conclusions. Hantzchel et al. [47] drawal and is not serious. Nausea, anorexia and vomiting are occasional side-effects which appear early in concluded that prednisolone accelerates the clinical improvement afforded by AZA, but does not necessarthe course of treatment, usually within the first few weeks. This is not dose related and responds to treatily magnify it; Bijlsma et al. [48] did not demonstrate any benefit in AZA-treated patients in whom methylment withdrawal, although it may occasionally preclude subsequent treatment. An increased risk of prednisolone pulse therapy was used in conjunction with AZA.
infection and accelerated nodulosis have also been reported [57, 58] . Hypersensitivity reactions to AZA are rare. Symptoms including nausea, diarrhoea, Toxicity Three side-effects dominate the picture of AZA arthralgia, rash, fever, rigors, hypotension, pneumonitis, pancreatitis, hepatitis, haematuria and renal toxicity: marrow suppression, gastrointestinal intolerance and infections. The reported incidence of sideinsufficiency resolve on withdrawal of the drug [59] [60] [61] [62] . These clinical features may be confused with septic effects varies considerably from one study to another; minor side-effects are common and major side-effects shock or organ rejection in transplantation. There has been concern regarding the potential including gastrointestinal upset and cytopenias occur in as many as 30% of patients. Singh et al. [49] association between AZA treatment and malignant disease since early reports from the transplantation reported on 546 AZA-treated patients surveyed prospectively and concluded that AZA presents a surprisliterature suggested a link [63, 64] . In RA patients, this link is less clear-cut, although malignancies have ingly benign profile, with very few serious therapeutic mishaps. The most frequently reported side-effects were been reported in AZA-treated patients [65, 66 ] . Kinlen et al. [67] studied 1349 non-transplant patients who nausea, vomiting and leucopenia. Gastrointestinal intolerance accounted for nearly 60% of therapy interhad been treated for at least 3 months with AZA, CP or chlorambucil. There was an increase in the incidence ruptions in 95 patients. AZA had to be discontinued in eight patients due to leucopenia; however, in only of the following malignancies in these patients: nonHodgkin's lymphoma (four cases as against 0.34 two cases was the leucopenia severe enough to cause major clinical problems or hospitalization. In neither expected), squamous cell skin carcinoma (two cases as against 0.38 expected), all other tumours (34 cases as of these two cases was the infection of a life-threatening nature. Of 81 hospitalizations for all causes, only eight against 21.74 expected); however, the mortality data did not show any significant excess. This pattern of were partly related to AZA, and no deaths were attributed to AZA therapy. No lymphomas or leuincreased incidence of malignancies is similar to that seen in transplant recipients and the excess of nonkaemias were detected; the overall incidence of neoplasms was similar to that seen in RA patients receiving Hodgkin's lymphoma was evident soon after starting immunosuppressive therapy. Matteson et al. [68] estabconventional therapy. McKendry et al. [41] treated 131 patients with either AZA (n = 37) or MTX (n = lished the RA AZA Registry (RAAR) in 1982 to examine the safety of AZA and other DMARDs in 94) for a mean time period of 38 ± 23.3 months in the treatment of RA. After 7 yr, 20 malignancies had $ There is conflicting evidence regarding the influence of AZA on radiographic progression. been reported in 530 DMARD-treated adult patients $ It has a slow onset of action, reaching a peak after with RA, suggesting that there may be an increased~4 -6 months of therapy. risk of malignancy, particularly lymphoproliferative $ A reduction of concomitant corticosteroid dosage is disorders. In contrast, Lewis et al. [69] reported the usually possible. results of a prospective study of 311 patients with RA.
$ Treatment continues to be effective for long periods Two hundred and three of this group had been treated of time. with AZA (52 also received chlorambucil or CP). The $ Withdrawal of therapy leads to relapse. overall death rate from neoplasia was higher than $ A dosage of 2.0-2.5 mg/kg/day is necessary to maxiexpected in the age group 45-64 yr and lower in those mize clinical effectiveness. aged 75 and over; it should be noted that deaths were $ Adverse events are more common at higher dosage. not more common in patients receiving AZA.
$ Reductions in ESR and RF titres are inconstant Hazleman [70] suggested that the incidence of most of findings and a poor guide to clinical response. the common cancers was less in RA patients treated $ Combination studies using AZA have been with AZA than in RA patients in general. Wessel et al. disappointing. [71] did not demonstrate any increased incidence of $ Common adverse events include gastrointestinal neoplasia in either RA or SLE patients treated with intolerance and marrow suppression. AZA compared with a control population. AZA has $ There may be a small increased risk of malignancy, also been reported to give rise to chromosomal abnorparticularly lymphoproliferative disorders. malities [72] . Hunter et al. [19] reported an increased $ The efficacy-toxicity ratio of AZA justifies its incluincidence of chromosomal abnormalities (13.8% vs sion in the list of therapeutic options in RA. 6.9% in age-, sex-and duration-of-disease-matched RA controls and 4.7% in healthy controls), in a study of 12 patients taking AZA for 40 months. These observa-CYCLOPHOSPHAMIDE tions are challenged by another long-term study in Pharmacology SLE [73] .
CP is an alkylating agent of the nitrogen mustard Monitoring and practical management considerations.
class. The phosphoester ring must be broken for it to AZA should be started at an initial dose of 50 mg be 'active' and this occurs in the liver. Active metaboldaily for the first week. If tolerated, the dosage should ites of CP (e.g. phosphoramide mustard ) cross-link then be increased to 2.5 mg/kg/day. A full blood count DNA so that it is unable to replicate. CP is cytotoxic and liver function tests are recommended fortnightly to resting and dividing lymphocytes. In RA patients, for the first 4 weeks and monthly thereafter. If the it suppresses T-helper function, and reduces the numtotal white cell count falls below 3000/mm3, treatment bers of activated T cells and B cells. should be stopped. Lesser falls are an indication for CP and its metabolites are excreted mainly in the more frequent monitoring and dosage reduction should urine. It is extensively metabolized before excretion be considered. If it is necessary to stop treatment due with less than a quarter of any administered dose to leucopenia, it may be possible to reintroduce AZA appearing in the urine unchanged. The urinary at a lower dose when the bone marrow has recovered. metabolites include carboxyphosphamide and 4-ketoNausea and gastrointestinal complications can often phosphamide. Acrolein is a metabolite which is be reduced or eliminated by dosage reduction, patients excreted in the urine and is thought to be responsible with hypersensitivity reactions cannot be treated with for bladder toxicity, which may be helped by the agent AZA again. Despite reports of chromosome aberraMesna (mercaptoethanesulphonate) which detoxifies tions [72, 73] , or fetal growth retardation [74] in the acrolein. Very small amounts of CP appear in faeces, offspring of mothers who received AZA during pregexpired air, cerebrospinal fluid, sweat, breast milk, nancy, there seems to be little evidence that AZA is saliva or synovial fluid. Dialysis removes almost threeteratogenic in humans. Given the nature of the severe quarters of any administered dose of CP so patients chronic conditions for which AZA is generally used, with renal failure need to have their drug administered discontinuing therapy in patients who become pregnant after dialysis. may not be necessary or desirable; however, it is best to avoid AZA during pregnancy when possible. In Efficacy patients with renal failure and those receiving allopuriOral CP has consistently been shown to be better nol therapy, the AZA dosage should be reduced.
than placebo both in clinical assessment and in laboratory assessment of active arthritis when used in doses of >1.5 mg/kg/day. Two studies have shown beneficial Summary effect on bone destruction. It is clinically equal to $ AZA is effective at achieving disease suppression AZA, possibly superior to i.m. gold clinically and in in RA.
retarding bone destruction. Studies in general suggest $ Its efficacy is comparable to other disease-modifying that the benefits take some time to develop (4 months) drugs, including chloroquine, gold and cyclosporin, with efficacy maintained for up to 25 months. After withdrawal of CP, patients usually have a relapse. although it is less effective than MTX.
Non-articular complications such as lung disease, also been used to treat inflammatory arthritis, but was found to be ineffective by Arnold et al. [83] . ulcers and neuropathy may also respond to treatment.
Despite the use of CP as an immunosuppressive cytotoxic agent in malignant disease, its exact role and Combination therapy Most of the combination therapies have been with mode of action in RA are still uncertain. A recent review by Curtis et al. [75] for a mean of 27 months. There was a good effect [77] who in 1983 described three patients who had clinically with some evidence to show a reduction in failed conventional second-line therapy who were given erosions. In a follow-up studied published by the same oral CP often with pulse methlyprednisolone, and who authors in 1986 [44] with increased numbers they showed quite dramatic responses. They were able to noted that the benefit had been maintained, but four reduce the dose of CP, which was initially given daily, of the 31 patients had developed malignancy and the but later every third or fourth day. The early studies authors suggested replacing CP with a non-alkylating in rheumatoid vasculitis and the studies in other comagent. Even with this quite prolonged long-term followplications of RA were also open studies, including that up, they still felt that the place of this combination of Abel et al. [3] who reported quite dramatic improvetherapy was uncertain without controlled trials. ment in systemic vasculitis in five patients treated with continuous oral CP.
Toxicity
The main concern about the use of CP is in relation to its toxicity. Most of the reported studies relate to
Comparative and controlled studies
The co-operating clinics study in 1970 reported the the use of continuous oral CP. In RA, the dose often has to be reduced with time due to increased sensitivity effect of high and very-low-dose CP in 48 patients followed for 32 weeks, showing a better response in of patients' neutrophil counts to the drug. However, marrow toxicity has not been a major problem in the high-dose group [78] . A similar study by Williams et al. [79] in 1980 comparing 150 mg/day with most studies. The biggest cause of concern has been bladder 75 mg/day showed similar clinical efficacy in both groups.
toxicity. Early studies showed the relationship between acrolein and haemorrhagic cystitis and also bladder Currey et al. [23] compared AZA, cyclophosphamide and gold, and found CP to be 'marginally the most fibrosis [86 ] , and it is thought that cystitis and fibrosis may be linked to an increased risk of bladder cancer, effective drug but prone to cause azoospermia' and expressed concern about its long-term risk of possibly exacerbated by suppression of immune surveillance [87] . Early studies in RA confirmed an increased malignancy.
Lidsky et al. [80] undertook a double-blind placeborisk of bladder cancer up to 4.1 times expected when compared with rheumatoid controls [88, 89] . Baker controlled study in 22 patients using relatively lowdose CP (0.87-1 mg/kg) and showed no difference et al. [90] studied 119 rheumatoid patients treated with oral CP compared with 119 controls and described 37 between placebo and CP treatment. Townes et al. [81] , in a double-blind cross-over study, noted significant malignancies in 29 of the CP-treated patients compared with 16 malignancies in 16 controls (P < 0.05). Bladder clinical benefit with a higher dose of CP, but also expressed concern about the numbers of patients with cancer was only seen in the rheumatoid patients (6) and there was also an increase in skin and haematohaemorrhagic cystitis and with amenorrhoea as a consequence of CP treatment. Smyth et al. [82] in 1975 logical cancers. These patients were further followed by Radis et al.
[91] in a 20 yr follow-up which showed compared prednisolone plus placebo (16 patients) with prednisolone plus oral CP (13 patients) and again that the numbers of malignancies had increased to 50 in 37 CP patients compared with 26 in 25 controls noted clinical benefit only in patients on high-dose CP which was also associated with increased toxicity.
(relative risk 1.5). The numbers of bladder cancers had increased to nine, skin cancers to 19 and the important Intravenous pulse CP was originally described by Scott and Bacon [4] to be effective for systemic vasculfinding was that three of the bladder cancers developed 14, 16 and 17 yr after CP was stopped. A review by itis when compared with conventional second-line therapy including oral AZA. Intravenous pulse CP has Jones et al. [92] looking at the malignancy risk and mortality associated with immunosuppressive treatstudy showed a significant increased risk of infection in the oral CP plus steroid group compared with pulse ment in RA showed only a relatively small increase in mortality with immunosuppression, but most of the CP and Omdal et al. [97] reported severe infections in 24% of patients treated with oral CP. Our own studies excess deaths were due to malignancy with a relative risk of 4.2 (1.7-10) and a relatively risk of immune with pulse CP have shown severe bacterial infections in only 12% overall-16% of patients with vasculitis system malignancy of 7 (0.9-56.5). In this group, the increase in malignancy associated with CP was due to complicating RA. two patients developing bladder cancer.
Conclusions The concerns about CP-induced cystitis and bladder CP is a powerful immunosuppressive agent which is cancer have recently been reviewed in patients with clinically effective in the treatment of RA when given Wegener's granulomatosis by Talar-Williams et al.
as continuous oral treatment. The toxicity is, however, [93] . Their conclusions were that 'long-term oral CP considerable with a high risk of immunological maligtherapy is associated with substantial urotoxicity nancy and a particularly high risk of bladder cancer. including the development of transitional cell carcinBecause of this, it is no longer used routinely. CP does oma of the urinary bladder'. In their cohort of patients, have a role in the treatment of more life-threatening the estimated incidence of bladder cancer after their systemic complications of RA, particularly vasculitis, first exposure to CP was 5% at 10 yr and 16% at 15 yr.
where there may be a reduction in dosage and toxicity The only trials to compare pulsed i.v. CP with oral if the CP is given i.v. Intravenous CP is ineffective for therapy have been undertaken in the systemic vasculittreating inflammatory arthritis. ides. Adu et al. [94] randomized 54 patients with systemic vasculitis to treatment with either pulse CP Cyclophosphamide current issues and prednisolone or continuous oral prednisolone and CP. The patients on continuous CP were more likely $ Oral CP is now rarely used to treat rheumatoid to develop leucopenia and had slightly increased treatsynovitis. ment-related toxicity compared with pulse CP. There $ CP is effective in the treatment of systemic vasculitis, was, however, little difference in terms of deaths, severe SLE and severe extra-articular manifestations relapses, treatment failures, improvement in disease of RA (especially vasculitis). activity scores or renal function. Guillevin et al. [95] $ The most worrying side-effects of continuous oral undertook a similar study comparing steroids and CP are haemorrhagic cystitis and bladder cancer. pulse CP vs steroids and oral CP in the treatment of Previous research suggests that this is a cumulative Wegener's granulomatosis. They found pulse CP as problem which may develop decades after treatment effective as oral CP in achieving initial remission and has discontinued. associated with fewer side-effects and lower mortality.
$ The most effective method of delivery of CP is However, in the longer term, treatment with pulse CP controversial. Some data suggest that pulsed i.v. was not able to maintain remission or prevent relapses therapy is as effective as continuous oral CP in the as well as oral CP. Our own experience with 66 patients short term for 'remission induction', and less toxic. given pulse CP and steroids is that it is a well-tolerated, Late relapses may occur more commonly with pulsed safe and effective short-term treatment for systemic i.v. treatment, although they are usually relatively vasculitis with lower toxicity, including malignancy, mild. when compared with reported series using continuous $ Pulsed i.v. CP is ineffective treatment for rheumatoid oral CP. However, our follow-up is only for a maxsynovitis. It may even cause a mild flare of the imum of 7 yr and longer term studies with pulse CP synovitis. are needed before the picture is completely clear.
One of the intriguing findings in patients given pulse R CP for systemic vasculitis complicating RA is that combination of CP with corticosteroids. Guillevin's
